These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 21880831)

  • 1. Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury.
    Awad AS; Kinsey GR; Khutsishvili K; Gao T; Bolton WK; Okusa MD
    Am J Physiol Renal Physiol; 2011 Dec; 301(6):F1358-66. PubMed ID: 21880831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Podocyte-specific chemokine (C-C motif) receptor 2 overexpression mediates diabetic renal injury in mice.
    You H; Gao T; Raup-Konsavage WM; Cooper TK; Bronson SK; Reeves WB; Awad AS
    Kidney Int; 2017 Mar; 91(3):671-682. PubMed ID: 27914709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophage-derived tumor necrosis factor-α mediates diabetic renal injury.
    Awad AS; You H; Gao T; Cooper TK; Nedospasov SA; Vacher J; Wilkinson PF; Farrell FX; Brian Reeves W
    Kidney Int; 2015 Oct; 88(4):722-33. PubMed ID: 26061548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of CCL2/CCR2 signalling ameliorates diabetic nephropathy in db/db mice.
    Seok SJ; Lee ES; Kim GT; Hyun M; Lee JH; Chen S; Choi R; Kim HM; Lee EY; Chung CH
    Nephrol Dial Transplant; 2013 Jul; 28(7):1700-10. PubMed ID: 23794669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arginase-2 mediates diabetic renal injury.
    Morris SM; Gao T; Cooper TK; Kepka-Lenhart D; Awad AS
    Diabetes; 2011 Nov; 60(11):3015-22. PubMed ID: 21926276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a CCR2 antagonist on macrophages and Toll-like receptor 9 expression in a mouse model of diabetic nephropathy.
    Ito S; Nakashima H; Ishikiriyama T; Nakashima M; Yamagata A; Imakiire T; Kinoshita M; Seki S; Kumagai H; Oshima N
    Am J Physiol Renal Physiol; 2021 Dec; 321(6):F757-F770. PubMed ID: 34719947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice.
    Kang YS; Lee MH; Song HK; Ko GJ; Kwon OS; Lim TK; Kim SH; Han SY; Han KH; Lee JE; Han JY; Kim HK; Cha DR
    Kidney Int; 2010 Nov; 78(9):883-94. PubMed ID: 20686445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loganin alleviates macrophage infiltration and activation by inhibiting the MCP-1/CCR2 axis in diabetic nephropathy.
    Du Q; Fu YX; Shu AM; Lv X; Chen YP; Gao YY; Chen J; Wang W; Lv GH; Lu JF; Xu HQ
    Life Sci; 2021 May; 272():118808. PubMed ID: 33245967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined inhibition of CCR2 and ACE provides added protection against progression of diabetic nephropathy in
    Tesch GH; Pullen N; Jesson MI; Schlerman FJ; Nikolic-Paterson DJ
    Am J Physiol Renal Physiol; 2019 Dec; 317(6):F1439-F1449. PubMed ID: 31566438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deficiency of cannabinoid receptor of type 2 worsens renal functional and structural abnormalities in streptozotocin-induced diabetic mice.
    Barutta F; Grimaldi S; Franco I; Bellini S; Gambino R; Pinach S; Corbelli A; Bruno G; Rastaldi MP; Aveta T; Hirsch E; Di Marzo V; Gruden G
    Kidney Int; 2014 Nov; 86(5):979-90. PubMed ID: 24827776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the monocyte chemoattractant protein-1/C-C chemokine receptor 2 signaling pathway in transient receptor potential vanilloid type 1 ablation-induced renal injury in salt-sensitive hypertension.
    Wang Y; Zhu M; Xu H; Cui L; Liu W; Wang X; Shen S; Wang DH
    Exp Biol Med (Maywood); 2015 Sep; 240(9):1223-34. PubMed ID: 25585624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed Treatment with a Small Pigment Epithelium Derived Factor (PEDF) Peptide Prevents the Progression of Diabetic Renal Injury.
    Awad AS; You H; Gao T; Gvritishvili A; Cooper TK; Tombran-Tink J
    PLoS One; 2015; 10(7):e0133777. PubMed ID: 26207369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice.
    Sullivan T; Miao Z; Dairaghi DJ; Krasinski A; Wang Y; Zhao BN; Baumgart T; Ertl LS; Pennell A; Seitz L; Powers J; Zhao R; Ungashe S; Wei Z; Boring L; Tsou CL; Charo I; Berahovich RD; Schall TJ; Jaen JC
    Am J Physiol Renal Physiol; 2013 Nov; 305(9):F1288-97. PubMed ID: 23986513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism.
    You H; Gao T; Cooper TK; Morris SM; Awad AS
    Kidney Int; 2013 Dec; 84(6):1189-97. PubMed ID: 23760286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophages directly mediate diabetic renal injury.
    You H; Gao T; Cooper TK; Brian Reeves W; Awad AS
    Am J Physiol Renal Physiol; 2013 Dec; 305(12):F1719-27. PubMed ID: 24173355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes.
    Sayyed SG; Ryu M; Kulkarni OP; Schmid H; Lichtnekert J; Grüner S; Green L; Mattei P; Hartmann G; Anders HJ
    Kidney Int; 2011 Jul; 80(1):68-78. PubMed ID: 21508925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy.
    Barutta F; Bellini S; Mastrocola R; Gambino R; Piscitelli F; di Marzo V; Corbetta B; Vemuri VK; Makriyannis A; Annaratone L; Bruno G; Gruden G
    Br J Pharmacol; 2018 Dec; 175(23):4371-4385. PubMed ID: 30184259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tim-3 aggravates podocyte injury in diabetic nephropathy by promoting macrophage activation via the NF-κB/TNF-α pathway.
    Yang H; Xie T; Li D; Du X; Wang T; Li C; Song X; Xu L; Yi F; Liang X; Gao L; Yang X; Ma C
    Mol Metab; 2019 May; 23():24-36. PubMed ID: 30862474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. l-Homoarginine supplementation prevents diabetic kidney damage.
    Wetzel MD; Gao T; Venkatachalam M; Morris SM; Awad AS
    Physiol Rep; 2019 Sep; 7(18):e14235. PubMed ID: 31552707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic Monocyte Chemotactic Protein-1 Inhibition Modifies Renal Macrophages and Restores Glomerular Endothelial Glycocalyx and Barrier Function in Diabetic Nephropathy.
    Boels MGS; Koudijs A; Avramut MC; Sol WMPJ; Wang G; van Oeveren-Rietdijk AM; van Zonneveld AJ; de Boer HC; van der Vlag J; van Kooten C; Eulberg D; van den Berg BM; IJpelaar DHT; Rabelink TJ
    Am J Pathol; 2017 Nov; 187(11):2430-2440. PubMed ID: 28837800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.